Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Asahi Intecc (7747 JP): FY26 Ends on Strong Note; FY27 Guidance Initiation; MTM Plan Revised Upward

Asahi Intecc (7747 JP): Medical Division Drives 9M Result; FY25 Guidance Raised; Buyback Announced

Asahi Intecc (7747 JP): Strong FY25 Result; FY26 Guidance Initiation; New Business Plan Announced

Asahi Intecc (7747 JP): Strong Demand Drives H1FY26 Performance and FY26 Guidance Raise

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> reported strong financial performance for the first three quarters of FY26, with revenue and operating profit reporting double-digit growth and net profit recording triple-digit growth.</li>
<li>Revenue from medical division increased 15% YoY to ¥95B, driven by broad-based growth covering all geographical regions and treatment fields. Key markets including U.S., Europe, and China reported double-digit growth.</li>
<li>With 9MFY26 revenue, operating profit, and net profit recording progress rate of 77%, 89%, and 87% against full-year forecast, the company is well-positioned to meet FY guidance.</li>
</ul>



Asahi Intecc (7747 JP) reported strong financial performance for the first three quarters of FY26, with revenue and operating profit reporting double-digit growth and net profit recording triple-digit growth.
Revenue from medical division increased 15% YoY to ¥95B, driven by broad-based growth covering all geographical regions and treatment fields. Key markets including U.S., Europe, and China reported double-digit growth.
With 9MFY26 revenue, operating profit, and net profit recording progress rate of 77%, 89%, and 87% against full-year forecast, the company is well-positioned to meet FY guidance.


Asahi Intecc (7747 JP): Well-Positioned to Meet FY Guidance; Long-Term Growth Levers Intact